[go: up one dir, main page]

HUE066587T2 - Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor - Google Patents

Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor

Info

Publication number
HUE066587T2
HUE066587T2 HUE18851555A HUE18851555A HUE066587T2 HU E066587 T2 HUE066587 T2 HU E066587T2 HU E18851555 A HUE18851555 A HU E18851555A HU E18851555 A HUE18851555 A HU E18851555A HU E066587 T2 HUE066587 T2 HU E066587T2
Authority
HU
Hungary
Prior art keywords
exon
selective inhibitor
mutant egfr
egfr selective
mutant
Prior art date
Application number
HUE18851555A
Other languages
English (en)
Inventor
Naomi Abe
Shinichi Hasako
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of HUE066587T2 publication Critical patent/HUE066587T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE18851555A 2017-09-01 2018-08-31 Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor HUE066587T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017168606 2017-09-01

Publications (1)

Publication Number Publication Date
HUE066587T2 true HUE066587T2 (hu) 2024-08-28

Family

ID=65527547

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18851555A HUE066587T2 (hu) 2017-09-01 2018-08-31 Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor

Country Status (23)

Country Link
US (1) US11701359B2 (hu)
EP (1) EP3677266B1 (hu)
JP (1) JP7065103B2 (hu)
KR (1) KR102676530B1 (hu)
CN (2) CN117159551A (hu)
AU (1) AU2018325819B2 (hu)
CA (1) CA3074418C (hu)
DK (1) DK3677266T5 (hu)
ES (1) ES2972895T3 (hu)
FI (1) FI3677266T3 (hu)
HU (1) HUE066587T2 (hu)
IL (1) IL272929B2 (hu)
JO (1) JOP20200044A1 (hu)
MX (1) MX2020002296A (hu)
MY (1) MY199676A (hu)
NZ (1) NZ762195A (hu)
PH (1) PH12020500419A1 (hu)
PL (1) PL3677266T3 (hu)
PT (1) PT3677266T (hu)
SG (1) SG11202001861WA (hu)
TW (1) TWI838345B (hu)
WO (1) WO2019045036A1 (hu)
ZA (1) ZA202001445B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
FI3677266T3 (fi) 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
FI3902548T3 (fi) * 2018-12-28 2025-07-17 Taiho Pharmaceutical Co Ltd Hoitoresistentin L718- ja/tai L792-mutaation omaavan EGFR:n inhibiittori käytettäväksi syövän hoitamisessa
WO2022055895A1 (en) * 2020-09-08 2022-03-17 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
BR112023021111A2 (pt) 2021-04-13 2023-12-19 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
TW202515577A (zh) * 2023-06-27 2025-04-16 日商大鵬藥品工業股份有限公司 患有具有egfr畸變的非小細胞肺癌之個體的治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
KR20070113295A (ko) 2005-03-17 2007-11-28 노파르티스 아게 티로신/트레오닌 키나제 억제제, 특히 b-raf 키나제억제제로서의n-[3-(1-아미노-5,6,7,8-테트라히드로-2,4,4b-트리아자플루오렌-9-일)-페닐]벤즈아미드
PL1800675T4 (pl) 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
MY152972A (en) 2009-07-10 2014-12-15 Taiho Pharmaceutical Co Ltd Azabicyclo compound and salt thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2662357B1 (en) 2011-01-07 2016-08-03 Taiho Pharmaceutical Co., Ltd. Bicyclic compounds or salts thereof for use in the treatment of cancer
JP5878178B2 (ja) 2011-09-30 2016-03-08 大鵬薬品工業株式会社 1,2,4−トリアジン−6−カルボキサミド誘導体
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
CN104136438B (zh) 2012-02-23 2016-04-06 大鹏药品工业株式会社 喹啉基吡咯并嘧啶基稠环化合物或其盐
AU2014219754B2 (en) 2013-02-22 2016-05-05 Taiho Pharmaceutical Co., Ltd. Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method
TWI603971B (zh) 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ, インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
AP2017009690A0 (en) 2014-06-19 2017-01-31 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
JP6583614B2 (ja) 2015-05-11 2019-10-02 大同特殊鋼株式会社 アーク炉の電極折損防止装置
FI3677266T3 (fi) 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori

Also Published As

Publication number Publication date
EP3677266B1 (en) 2024-01-17
IL272929B2 (en) 2024-05-01
KR20200044918A (ko) 2020-04-29
CN111465397A (zh) 2020-07-28
US20200253975A1 (en) 2020-08-13
BR112020004000A2 (pt) 2020-10-20
TWI838345B (zh) 2024-04-11
EP3677266A1 (en) 2020-07-08
FI3677266T3 (fi) 2024-03-22
CA3074418A1 (en) 2019-03-07
DK3677266T3 (da) 2024-04-22
CA3074418C (en) 2024-04-23
WO2019045036A1 (ja) 2019-03-07
AU2018325819A1 (en) 2020-03-19
IL272929B1 (en) 2024-01-01
CN117159551A (zh) 2023-12-05
TW201912160A (zh) 2019-04-01
AU2018325819B2 (en) 2024-02-01
PH12020500419A1 (en) 2021-03-01
NZ762195A (en) 2025-08-29
SG11202001861WA (en) 2020-04-29
PT3677266T (pt) 2024-03-04
MX2020002296A (es) 2020-09-10
US11701359B2 (en) 2023-07-18
KR102676530B1 (ko) 2024-06-20
ES2972895T3 (es) 2024-06-17
EP3677266A4 (en) 2021-05-12
JP7065103B2 (ja) 2022-05-11
DK3677266T5 (da) 2024-08-26
RU2020112357A (ru) 2021-10-04
CN111465397B (zh) 2023-10-13
JPWO2019045036A1 (ja) 2020-10-15
MY199676A (en) 2023-11-16
ZA202001445B (en) 2023-10-25
PL3677266T3 (pl) 2024-07-01
CA3224526A1 (en) 2019-03-07
JOP20200044A1 (ar) 2020-02-26
RU2020112357A3 (hu) 2022-02-18
IL272929A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
PL3677266T3 (pl) Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21
IL266239A (en) Selective inhibitor of egfr with exon 20 insertion mutation
IL280134A (en) Anti-CD112R preparations and methods
ZA202002172B (en) Pde9 inhibitor and use thereof
IL288872A (en) Imidazopyrimidines as eed inhibitors and their use
HUE061331T2 (hu) Mutáns IDH-1 gátlása
GB2591554B (en) Composiitons and methods and uses relating thereto
SG11202104448WA (en) Compositions and methods
GB201817444D0 (en) Methods and compositions
IL284330A (en) Treatment-resistant EGFR inhibitor mutant L718 and/or L792
GB201819987D0 (en) Methods and compositions
GB202102659D0 (en) Drilling systems and methods
GB201906169D0 (en) Drilling systems and methods
GB201804092D0 (en) Methods and compositions
IL276476B1 (en) Crystalline EGFR inhibitor and its uses
IL269723A (en) Mixtures containing mutant alpha-1-antitrypsin and their use
GB2579366B (en) Drilling systems and methods
GB2594831B (en) Rheometer systems and related methods
PL3720442T3 (pl) Hamowanie mutanta idh-1
GB2587571B (en) Drilling systems and methods
GB201902266D0 (en) New methods and uses
GB202101948D0 (en) Drilling systems and methods
GB201812776D0 (en) New methods and uses
GB201817902D0 (en) Methods and compositions
GB201809880D0 (en) Compositions and methods